Atlanta Clinical and Translational Science Institute   Report issue

Academic/Hospital Phase 1 Phase 3
Founded: Atlanta GA United States (2007)

Organization Overview

First Clinical Trial
2007
NCT00892554
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Atlanta Clinical and Translational Science Institute

Active Ingredients

Drugs in Phase 3 Trials (3)

morphine (1 trial)

nalbuphine (nubain) (1 trial)

propranolol (inderal) (1 trial)

Drugs in Phase 1 Trials (1)

autologous mesenchymal stem cells (1 trial)

Drugs in Other Trials (1)

docosahexaenoic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 3)

Crohn Disease (Phase 1)

Dyskinesias (Phase 3)

Tardive Dyskinesia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 5